HomeCONGRESS

CONGRESS

View Category
Day 2

GAUSS -2: Evolocumab effective in reducing LDL cholesterol in patients intolerant to statins

Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption...
solaci -
Learn More
Day 2

ALECARDIO Trial: Aleglitazar associated with severe adverse events in diabetic patients with acute coronary syndrome

This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile...
solaci -
Learn More
Day 3

POISE -2: Clonidine does not reduce the risk of perioperative death or myocardial infarction in patients undergoing noncardiac surgery

There is some evidence that clonidine administered in small doses for short periods of time prior to...
solaci -
Learn More
Day 3

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility...
solaci -
Learn More
Day 1

CoreValve superior to surgical aortic valve replacement in high-risk patients

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve...
solaci -
Learn More
Day 1

SYMPLICITY HTN -3: Negative results of renal denervation in patients with resistant hypertension.

Previous studies have shown that renal denervation in a 3-year period, reduced the blood pressure in resistant...
solaci -
Learn More
Day 2

CHOICE Trial: Same mortality, less aortic regurgitation and need for a second prosthetic for Edwards Sapien XT valve versus Medtronic CoreValve

So far, there had been no published randomized studies comparing balloon-expandable Edwards’s prosthesis and self-expandingCoreValve. The aim...
solaci -
Learn More
Day 2

STABILITY Trial: Daraplabid no benefits in chronic coronary artery disease

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing...
solaci -
Learn More